leon-nanodrugs and Bionpharma are partnering on the global development of a dermatological product using leon-nanodrugs’s MicroJet Reactor® (MJR) nanotechnology platform. Under terms of the collaboration, the firms will jointly develop the product at leon’s U.S.-based contract development and manufacturing organization (CDMO) partner CoreRx, which houses the MJR platform. New Jersey-based Bionpharma will carry out future marketing and distribution of the product in the U.S. and other markets.
Commenting on the agreement, Michael Mehler, Sc.D., CEO of leon-nanodrugs, said, “We are very pleased about the partnership with Bionpharma who share our vision to generate added value to therapeutic molecules through the unique attributes of our MicroJet Reactor Technology. In addition, this co-development is a key strategic step on our way to become a recognized global leader in nanotechnology-formulated pharmaceuticals.”
Specialty pharmaceutical company leon-nanodrugs is exploiting its MJR nanotechnology platform to develop novel oral and parenteral drug formulations and innovative drug combinations that exhibit properties such as improved water solubility or membrane permeability. In December 2016, the Munich, Germany-based firm reported teaming up with Instillo Group to develop a generic oncology drug using the MJR platform.
